Shopping Cart 0
Cart Subtotal
USD 0

Generics in the Netherlands

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 350

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 700

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 1050
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Generics in the Netherlands

Summary

Generics in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Netherlands generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

- The Dutch generics market had total revenues of USD 1.1bn in 2017, representing a compound annual growth rate (CAGR) of 2% between 2013 and 2017.

- Market consumption volume increased with a CAGR of 2.1% between 2013 and 2017, to reach a total of 76.1% in 2017.

- The Dutch government is actively stopping companies raising pharmaceutical prices in conjunction with the Belgian government, which is slowing generics market growth, as well as in the wider pharmaceutical industry.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the Netherlands

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the Netherlands

- Leading company profiles reveal details of key generics market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Netherlands generics market with five year forecasts by both value and volume

Reasons to buy

- What was the size of the Netherlands generics market by value in 2017?

- What will be the size of the Netherlands generics market in 2022?

- What factors are affecting the strength of competition in the Netherlands generics market?

- How has the market performed over the last five years?

- How large is the Netherlands's generics market in relation to its regional counterparts?

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary 2

Market value 2

Market value forecast 2

Market volume 2

Market volume forecast 2

Geography segmentation 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 9

Market value 9

Market volume 10

Market Segmentation 11

Geography segmentation 11

Market Outlook 12

Market value forecast 12

Market volume forecast 13

Five Forces Analysis 14

Summary 14

Buyer power 15

Supplier power 16

New entrants 17

Threat of substitutes 18

Degree of rivalry 19

Leading Companies 20

Mylan N.V. 20

Novartis AG 24

Sanofi SA 28

Teva Pharmaceutical Industries Limited 31

Macroeconomic Indicators 34

Country data 34

Methodology 36

Industry associations 37

Related MarketLine research 37

Appendix 38

About MarketLine 38


List Of Figure

List of Figures

Figure 1: Netherlands generics market value: USD million, 2013-17

Figure 2: Netherlands generics market volume: % of total pharma, 2013-17

Figure 3: Netherlands generics market geography segmentation: % share, by value, 2017

Figure 4: Netherlands generics market value forecast: USD million, 2017-22

Figure 5: Netherlands generics market volume forecast: % of total pharma, 2017-22

Figure 6: Forces driving competition in the generics market in the Netherlands, 2017

Figure 7: Drivers of buyer power in the generics market in the Netherlands, 2017

Figure 8: Drivers of supplier power in the generics market in the Netherlands, 2017

Figure 9: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2017

Figure 10: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2017

Figure 11: Drivers of degree of rivalry in the generics market in the Netherlands, 2017

Figure 12: Mylan N.V.: revenues & profitability

Figure 13: Mylan N.V.: assets & liabilities

Figure 14: Novartis AG: revenues & profitability

Figure 15: Novartis AG: assets & liabilities

Figure 16: Sanofi SA: revenues & profitability

Figure 17: Sanofi SA: assets & liabilities

Figure 18: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 19: Teva Pharmaceutical Industries Limited: assets & liabilities


List Of Table

List of Tables

Table 1: Netherlands generics market value: USD million, 2013-17

Table 2: Netherlands generics market volume: % of total pharma, 2013-17

Table 3: Netherlands generics market geography segmentation: USD million, 2017

Table 4: Netherlands generics market value forecast: USD million, 2017-22

Table 5: Netherlands generics market volume forecast: % of total pharma, 2017-22

Table 6: Mylan N.V.: key facts

Table 7: Mylan N.V.: key financials (USD )

Table 8: Mylan N.V.: key financial ratios

Table 9: Novartis AG: key facts

Table 10: Novartis AG: key financials (USD )

Table 11: Novartis AG: key financial ratios

Table 12: Sanofi SA: key facts

Table 13: Sanofi SA: key financials (USD )

Table 14: Sanofi SA: key financials (EUR)

Table 15: Sanofi SA: key financial ratios

Table 16: Teva Pharmaceutical Industries Limited: key facts

Table 17: Teva Pharmaceutical Industries Limited: key financials (USD )

Table 18: Teva Pharmaceutical Industries Limited: key financial ratios

Table 19: Netherlands size of population (million), 2013-17

Table 20: Netherlands gdp (constant 2005 prices, USD billion), 2013-17

Table 21: Netherlands gdp (current prices, USD billion), 2013-17

Table 22: Netherlands inflation, 2013-17

Table 23: Netherlands consumer price index (absolute), 2013-17

Table 24: Netherlands exchange rate, 2013-17

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Generics, MarketLine, Netherlands


Companies

Mylan N.V.

Novartis AG

Sanofi SA

Teva Pharmaceutical Industries Limited